Testosterone undecanoate/D-alpha tocopherol - Lipocine
Alternative Names: LPCN-2401Latest Information Update: 14 Aug 2024
At a glance
- Originator Lipocine
- Class Anabolic steroids; Androstenols; Hormonal replacements; Obesity therapies; Small molecules; Testosterone congeners
- Mechanism of Action Androgen receptor agonists; Antioxidants; Fibroblast growth factor 2 stimulants; Lipolysis stimulants; Myogenic regulatory factor modulators; Myostatin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Obesity
Most Recent Events
- 08 Aug 2024 Lipocine plans to meet with FDA to discuss the development of LPCN 2401 as an aid to weight management interventions
- 08 Aug 2024 Lipocine re-initiates the phase II trial in Obesity in USA (PO)
- 12 Jul 2024 Testosterone undecanoate/D-alpha tocopherol - Lipocine is available for licensing as of 11 Apr 2024. https://www.lipocine.com/pipeline/